Biomarker Profiling in Stage 5 Chronic Kidney Disease Identifies the Relationship Between Angiopoietin-2 and Atrial Fibrillation

Overview

Journal Clin Appl Thromb Hemost

Publisher Sage Publications

Specialty Cardiology & Vascular Diseases

Date 2018 Oct 30

PMID 30370780

Citations 9

Authors

Jack Bontekoe

Justin Lee

Vinod Bansal

Mushabbar Syed

Debra Hoppensteadt

Paula Maia

Amanda Walborn

Jeffrey Liles

Eugene Brailovsky

Jawed Fareed

Affiliations

Soon will be listed here.

Abstract

Atrial fibrillation (AF) is prevalent in nearly 27% of patients with stage 5 chronic kidney disease on hemodialysis (CKD5-HD), suggesting a strong association between these 2 pathologies. It is hypothesized that the relationship between these 2 diseases may be mediated by inflammation. Angiopoietin-2 (Ang-2), a pro-inflammatory biomarker of endothelial instability, inflammation, and vascular remodeling, is elevated in CKD5-HD and AF, yet has not been evaluated in patients with concomitant AF and CKD5-HD. The aim of this study is to analyze circulating levels of inflammatory and thrombotic biomarkers in patients with concomitant AF and CKD5-HD. Plasma levels of Ang-2 were measured via sandwich enzyme-linked immunosorbent assay method in CKD5-HD patients (n = 96), patients with AF (n = 38), and controls (n = 50). Angiopoietin-2 was markedly elevated in CKD5-HD with comorbid AF as compared to CKD5-HD alone, and AF alone, respectively (13.05 ± 1.56 vs 9.57 ± 0.71 ng/mL; = .00169; vs 2.48 ± 0.57 ng/mL; < .0001). The results of this study suggest an additive effect of Ang-2 with coexistence of AF and CKD5-HD, which may be useful in the detection of AF within this patient population.

Citing Articles

Exploring Angiopoietin-2: Clinical Insights and Experimental Perspectives in Kidney Diseases.

Luo A, Chang F, Lin S Kidney Int Rep. 2024; 9(12):3375-3385.

PMID: 39698365 PMC: 11652073. DOI: 10.1016/j.ekir.2024.09.001.

Biomarker-based prediction of sinus rhythm in atrial fibrillation patients: the EAST-AFNET 4 biomolecule study.

Fabritz L, Al-Taie C, Borof K, Breithardt G, Camm A, Crijns H Eur Heart J. 2024; 45(47):5002-5019.

PMID: 39215973 PMC: 11646612. DOI: 10.1093/eurheartj/ehae611.

Angiopoietin-2 and Angiopoietin-like Proteins with a Prospective Role in Predicting Diabetic Nephropathy.

Alshawaf E, Abu-Farha M, Mohammad A, Devarajan S, Al-Khairi I, Cherian P Biomedicines. 2024; 12(5).

PMID: 38790911 PMC: 11118931. DOI: 10.3390/biomedicines12050949.

Myocardial Oedema as a Consequence of Viral Infection and Persistence-A Narrative Review with Focus on COVID-19 and Post COVID Sequelae.

Panagiotides N, Poledniczek M, Andreas M, Hulsmann M, Kocher A, Kopp C Viruses. 2024; 16(1).

PMID: 38257821 PMC: 10818479. DOI: 10.3390/v16010121.

Serum Angiopoietin-2 level increase differs between polytraumatized patients with and without central nervous system injuries.

Negrin L, Hajdu S Sci Rep. 2023; 13(1):19338.

PMID: 37935720 PMC: 10630405. DOI: 10.1038/s41598-023-45688-x.

References

van Meurs M, Kumpers P, Ligtenberg J, Meertens J, Molema G, Zijlstra J . Bench-to-bedside review: Angiopoietin signalling in critical illness - a future target?. Crit Care. 2009; 13(2):207. PMC: 2689450. DOI: 10.1186/cc7153. View

Yang K, Dudley Jr S . Oxidative stress and atrial fibrillation: finding a missing piece to the puzzle. Circulation. 2013; 128(16):1724-6. PMC: 3909513. DOI: 10.1161/CIRCULATIONAHA.113.005837. View

McManus D, Saczynski J, Ward J, Jaggi K, Bourrell P, Darling C . The Relationship Between Atrial Fibrillation and Chronic Kidney Disease : Epidemiologic and Pathophysiologic Considerations for a Dual Epidemic. J Atr Fibrillation. 2017; 5(1):442. PMC: 5153080. DOI: 10.4022/jafib.442. View

Vlachos K, Letsas K, Korantzopoulos P, Liu T, Georgopoulos S, Bakalakos A . Prediction of atrial fibrillation development and progression: Current perspectives. World J Cardiol. 2016; 8(3):267-76. PMC: 4807315. DOI: 10.4330/wjc.v8.i3.267. View

Davis S, Aldrich T, Jones P, Acheson A, Compton D, Jain V . Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell. 1996; 87(7):1161-9. DOI: 10.1016/s0092-8674(00)81812-7. View

Hu Y, Chen Y, Lin Y, Chen S . Inflammation and the pathogenesis of atrial fibrillation. Nat Rev Cardiol. 2015; 12(4):230-43. DOI: 10.1038/nrcardio.2015.2. View

Shlipak M, Fried L, Crump C, Bleyer A, Manolio T, Tracy R . Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation. 2003; 107(1):87-92. DOI: 10.1161/01.cir.0000042700.48769.59. View

Guo Y, Lip G, Apostolakis S . Inflammation in atrial fibrillation. J Am Coll Cardiol. 2012; 60(22):2263-70. DOI: 10.1016/j.jacc.2012.04.063. View

Bansal N, Fan D, Hsu C, Ordonez J, Marcus G, Go A . Incident atrial fibrillation and risk of end-stage renal disease in adults with chronic kidney disease. Circulation. 2013; 127(5):569-74. PMC: 3676734. DOI: 10.1161/CIRCULATIONAHA.112.123992. View

10.

Stack A, Bloembergen W . Prevalence and clinical correlates of coronary artery disease among new dialysis patients in the United States: a cross-sectional study. J Am Soc Nephrol. 2001; 12(7):1516-1523. DOI: 10.1681/ASN.V1271516. View

11.

Caglar K, Peng Y, Pupim L, Flakoll P, Levenhagen D, Hakim R . Inflammatory signals associated with hemodialysis. Kidney Int. 2002; 62(4):1408-16. DOI: 10.1111/j.1523-1755.2002.kid556.x. View

12.

Wells P, Anderson D, Rodger M, Forgie M, Kearon C, Dreyer J . Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. N Engl J Med. 2003; 349(13):1227-35. DOI: 10.1056/NEJMoa023153. View

13.

Lip G, Patel J, Hughes E, Hart R . High-sensitivity C-reactive protein and soluble CD40 ligand as indices of inflammation and platelet activation in 880 patients with nonvalvular atrial fibrillation: relationship to stroke risk factors, stroke risk stratification schema, and prognosis. Stroke. 2007; 38(4):1229-37. DOI: 10.1161/01.STR.0000260090.90508.3e. View

14.

Barrett B, Parfrey P, Morgan J, Barre P, Fine A, Goldstein M . Prediction of early death in end-stage renal disease patients starting dialysis. Am J Kidney Dis. 1997; 29(2):214-22. DOI: 10.1016/s0272-6386(97)90032-9. View

15.

Marcus G, Smith L, Ordovas K, Scheinman M, Kim A, Badhwar N . Intracardiac and extracardiac markers of inflammation during atrial fibrillation. Heart Rhythm. 2009; 7(2):149-54. PMC: 2900773. DOI: 10.1016/j.hrthm.2009.10.004. View

16.

Hwang S, Ballantyne C, Sharrett A, Smith L, Davis C, Gotto Jr A . Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. Circulation. 1998; 96(12):4219-25. DOI: 10.1161/01.cir.96.12.4219. View

17.

Freestone B, Chong A, Lim H, Blann A, Lip G . Angiogenic factors in atrial fibrillation: a possible role in thrombogenesis?. Ann Med. 2005; 37(5):365-72. DOI: 10.1080/07853890510037392. View

18.

Foley R, Parfrey P, Sarnak M . Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol. 2001; 9(12 Suppl):S16-23. View

19.

Naumnik B, Pawlak K, Mysliwiec M . Unfractionated heparin but not enoxaparin causes delayed plasma PAI-1 depletion in hemodialysis patients: a prospective study. Clin Appl Thromb Hemost. 2007; 15(1):84-91. DOI: 10.1177/1076029607304725. View

20.

Maisonpierre P, Suri C, Jones P, Bartunkova S, Wiegand S, Radziejewski C . Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science. 1997; 277(5322):55-60. DOI: 10.1126/science.277.5322.55. View